Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Rumpl3StiltSkinon Mar 28, 2021 12:43pm
190 Views
Post# 32894973

RE:RE:RE:Projected Math

RE:RE:RE:Projected Math
Pandora wrote:
Rumpl3StiltSkin wrote:
99942Apophis wrote: Yes CancerSlayer I have tried various projections for best and worse case scenarios without hard numbers but solely relying on full optimized protocol should show 75-80% in the 25 required patients. With each passing day those hard numbers draw closer my opinion and expectations are because of the initial fumble (TLT) management will make absolutely sure everything is spelled out to perfection with a resounding touchdown.  In my opinion out of the full 100-125 patients a net total CR could possibly score 90+% and again that is my biased opinion.


Yes Guys,

And at some point some analyst is going to notice that the CR % is approaching high 80s or low 90s. By then TLT should have multiple irons in the fire too, IMO. No brainer where SP will go from there. 
 


So all you 50 year olds can be quite optimistic :-))


Pando this data will be coming in over the next year or so. Will probably lead to something big like a buyout or major partnership. Hang in there.

<< Previous
Bullboard Posts
Next >>